For the current week, the overall ratings of four Biotechnology stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
ZIOPHARM Oncology‘s (NASDAQ:ZIOP) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. ZIOPHARM Oncology is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. In Portfolio Grader’s specific subcategories of Earnings Momentum, Equity, and Cash Flow, ZIOP also gets an F. The stock price has dropped 7.6% over the past month, worse than the 0.6% decrease the Nasdaq has seen over the same period of time. As of Nov. 28, 2012, 14.6% of outstanding ZIOPHARM Oncology shares were held short. For a full analysis of ZIOP stock, visit Portfolio Grader.
The rating of Progenics Pharmaceuticals (NASDAQ:PGNX) slips from a C to a D. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock gets F’s in Earnings Momentum, Earnings Revisions, Equity, and Sales Growth. Investors seem to agree with the downgrade and have pushed down the share price 22% over the past month. For more information, get Portfolio Grader’s complete analysis of PGNX stock.
Neurocrine Biosciences (NASDAQ:NBIX) experiences a ratings drop this week, going from last week’s C to a D. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. To get an in-depth look at NBIX, get Portfolio Grader’s complete analysis of NBIX stock.
Vical Inc.‘s (NASDAQ:VICL) rating falls this week to a F (“strong sell”), down from last week’s D (“sell”). Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Earnings Growth, Equity, and Sales Growth. Wall Street appears to agree with the stock downgrade, with share prices dropping 16.1% over the past month. For more information, get Portfolio Grader’s complete analysis of VICL stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.